Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Pharvaris is a clinical-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for hereditary angioedema (HAE), a rare genetic disorder causing unpredictable swelling attacks. The company's lead candidates, deucrictibant (PHA121) for on-demand treatment and PHA122 for prophylaxis, target a market dominated by injectable therapies, positioning Pharvaris to capture share through convenient oral administration. With no revenue and negative cash flow of $100M annually, the stock trades on clinical trial milestones, regulatory progress, and partnership potential.
Pharvaris operates a classic biotech development model: invest heavily in R&D to advance drug candidates through Phase 2/3 trials, obtain regulatory approval from FDA/EMA, then commercialize directly or through partnerships. The HAE market is estimated at $3-4B globally with high unmet need for oral therapies versus current injectables (Takeda's Takhzyro, BioCryst's Orladeyo). Pricing power is substantial in rare disease markets due to limited patient populations (estimated 1 in 50,000), high willingness-to-pay, and favorable reimbursement. The company's competitive advantage lies in its novel mechanism targeting bradykinin B2 receptors with potentially superior efficacy and safety versus existing oral options. Monetization likely occurs through US/EU commercial infrastructure buildout or strategic partnership with larger pharma for ex-US markets.
Phase 2/3 clinical trial data readouts for deucrictibant and PHA122 - efficacy endpoints (attack reduction, time to relief), safety profile versus placebo and active comparators
FDA and EMA regulatory milestone announcements - IND/NDA filings, Breakthrough Therapy designations, PDUFA date assignments, approval decisions
Partnership or licensing deal announcements with major pharma for commercialization rights, particularly ex-US territories
Cash runway updates and financing events - equity raises, debt facilities, or non-dilutive funding that extend operational runway beyond 12-18 months
Competitive developments in HAE market - approvals or setbacks for BioCryst (Orladeyo), Takeda, Ionis, or other oral HAE programs
Clinical trial failure risk - Phase 2/3 trials may not demonstrate statistical significance on primary endpoints (attack frequency reduction, time to symptom relief), or safety issues could emerge requiring program termination. Historical biotech Phase 3 success rates approximate 50-60%.
Regulatory approval uncertainty - FDA/EMA may require additional studies, reject NDA/MAA filings, or impose restrictive labels limiting commercial potential. Orphan drug designation provides some regulatory tailwinds but does not guarantee approval.
Reimbursement and pricing pressure - Payers increasingly scrutinize rare disease drug pricing despite orphan status. ICER cost-effectiveness reviews and European HTA bodies may limit pricing power below $300K+ annual treatment costs seen in earlier HAE launches.
BioCryst's Orladeyo (oral prophylaxis approved 2020) has first-mover advantage in oral HAE market with growing real-world evidence. Pharvaris must demonstrate superior efficacy or safety to capture share from established competitor.
Pipeline competition from Ionis, KalVista, and Astria Therapeutics developing alternative oral or subcutaneous HAE therapies with potentially differentiated mechanisms. Market may fragment across multiple oral options, limiting individual product penetration.
Cash runway risk - With $100M annual burn and approximately $230M cash (implied from 12.86x current ratio), the company has roughly 18-24 months of runway as of February 2026. Equity raises are likely required before commercialization, creating dilution risk for existing shareholders.
Equity financing risk in adverse market conditions - Biotech IPO/follow-on markets are cyclical. If capital markets deteriorate during cash needs, the company may face severely dilutive financing terms or inability to raise adequate capital.
low - Rare disease treatments are medically necessary and largely insulated from economic cycles. HAE patients require therapy regardless of GDP growth, and payer coverage for orphan drugs remains stable through recessions. However, biotech sector sentiment correlates with risk appetite, affecting stock volatility even when underlying business fundamentals are macro-insensitive.
Rising interest rates negatively impact Pharvaris through two channels: (1) Higher discount rates compress NPV of future cash flows, particularly punitive for pre-revenue biotechs with 3-5 year monetization timelines, and (2) Risk-off sentiment in growth/speculative equities reduces biotech sector multiples. The company's zero debt eliminates direct financing cost exposure, but equity financing becomes more expensive as investors demand higher returns. A 100bp Fed Funds increase historically correlates with 15-25% biotech index underperformance.
Minimal direct credit exposure given zero debt and strong current ratio of 12.86x. The company funds operations through equity markets rather than credit facilities. Indirectly, tighter credit conditions can reduce M&A activity and partnership valuations as potential acquirers face higher financing costs, potentially limiting exit optionality or deal premiums.
growth - Pharvaris attracts speculative growth investors and biotech specialists willing to accept binary clinical/regulatory risk for asymmetric upside potential. The 58.7% one-year return and zero revenue profile indicate momentum-driven trading around catalysts. Institutional biotech funds, hedge funds with healthcare focus, and retail investors seeking high-risk/high-reward exposure dominate the shareholder base. No dividend income or value characteristics given negative earnings and pre-commercial stage.
high - Clinical-stage biotechs exhibit extreme volatility with beta typically 1.5-2.5x market. Single-day moves of 30-50% are common around trial readouts or regulatory decisions. The 58.7% annual return with 20.9% six-month return demonstrates momentum volatility. Illiquidity in $1.8B market cap amplifies price swings. Options markets price elevated implied volatility (typically 60-100%) reflecting binary event risk.
